Transgene Biotek Ltd
About
[
edit
]
Transgene Biotek is engaged in the business of Research & Development.
[
add key points
]
- Market Cap ₹ 41.7 Cr.
- Current Price ₹ 5.50
- High / Low ₹ 6.85 / 3.03
- Stock P/E
- Book Value ₹ 1.29
- Dividend Yield 0.00 %
- ROCE -34.9 %
- ROE -53.3 %
- Face Value ₹ 10.0
Pros
- No pros found. Suggest something.
Cons
- Stock is trading at 4.26 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 23.64%
- Company has a low return on equity of -34.63% for last 3 years.
- Company might be capitalizing the interest cost
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 | 4 | 10 | 26 | 15 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
2 | 2 | 9 | 25 | 16 | 3 | 2 | 1 | 3 | 2 | 1 | 1 | 1 | |
Operating Profit | 2 | 2 | 1 | 1 | -1 | -2 | -2 | -1 | -3 | -2 | -1 | -1 | -1 |
OPM % | 45% | 41% | 12% | 4% | -5% | -188% | -503% | -633% | -914% | -1,750% | -971% | -369% | |
Other Income | 0 | 0 | 0 | 17 | 0 | -114 | 0 | 0 | 1 | 7 | 2 | 0 | 0 |
Interest | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 | 1 | 17 | 17 | 20 | 18 | 10 | 10 | 10 | 10 |
Profit before tax | 0 | 0 | 0 | 17 | -2 | -133 | -19 | -22 | -20 | -6 | -9 | -11 | -11 |
Tax % | 12% | 16% | 18% | 32% | 0% | 0% | 0% | 0% | 0% | -14% | 0% | 0% | |
Net Profit | 0 | 0 | 0 | 12 | -2 | -133 | -19 | -22 | -20 | -6 | -9 | -11 | -11 |
EPS in Rs | 0.24 | 0.24 | 0.03 | 1.77 | -0.30 | -17.61 | -2.51 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.40 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -100% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | 13% |
TTM: | -17% |
Stock Price CAGR | |
---|---|
10 Years: | -18% |
5 Years: | 25% |
3 Years: | 34% |
1 Year: | 70% |
Return on Equity | |
---|---|
10 Years: | -6% |
5 Years: | -20% |
3 Years: | -35% |
Last Year: | -53% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 16 | 41 | 66 | 66 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | 76 | |
Reserves | 100 | 100 | 175 | 245 | 256 | 121 | 102 | 79 | -34 | -41 | -50 | -61 | -66 |
Borrowings | 14 | 15 | 7 | 21 | 22 | 13 | 14 | 15 | 16 | 10 | 9 | 10 | 11 |
3 | 1 | 19 | 34 | 24 | 139 | 138 | 123 | 31 | 32 | 31 | 31 | 31 | |
Total Liabilities | 132 | 132 | 242 | 366 | 369 | 349 | 330 | 293 | 88 | 77 | 67 | 57 | 52 |
107 | 106 | 106 | 107 | 198 | 181 | 163 | 141 | 61 | 51 | 41 | 31 | 28 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 0 |
Investments | 0 | 0 | 0 | 0 | 92 | 92 | 92 | 92 | 0 | 0 | 0 | 0 | 0 |
25 | 26 | 135 | 259 | 78 | 76 | 74 | 60 | 25 | 24 | 24 | 24 | 24 | |
Total Assets | 132 | 132 | 242 | 366 | 369 | 349 | 330 | 293 | 88 | 77 | 67 | 57 | 52 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 4 | -1 | 25 | 100 | -2 | -1 | 0 | 0 | -1 | -2 | 0 | |
-3 | -5 | -67 | -144 | -101 | 1 | -0 | -0 | 0 | 3 | 2 | 0 | |
1 | 0 | 104 | 83 | 2 | 1 | 1 | 0 | 0 | -2 | 0 | -0 | |
Net Cash Flow | 0 | -0 | 36 | -36 | 0 | -0 | -0 | 0 | 0 | 0 | 0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
ROCE % | 1% | 1% | 0% | 6% | -1% | -7% | -9% | -12% | -17% | -15% | -26% | -35% |
Debtor Days | 58 | 53 | 254 | 395 | 448 | 6,867 | 19,941 | 3,305 | 13 | 0 | 0 | |
Inventory Turnover | 0.12 | 0.41 | 12.30 | 27.15 | 26.93 | 2.75 | 2.43 | 1.43 | 1.71 | 1.82 | 2.57 | 4.86 |
Documents
Recent announcements
- Compliance Certificate Pursuant To Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015. 8 Apr
- Statement Of Investor Complaints For The Quarter Ended March 2021 3 Apr
- Closure of Trading Window 3 Apr
- COLLABORATION FOR PROVIDING ORAL AND NASAL FORMULATIONS FOR COVID VACCINE UNDER DEVELOPMENT. 17 Mar
- Unaudited Standalone And Consolidated Financial Results Along With Limited Review Report Of The Company For The Quarter Ended 31St December 2020. 23 Jan
View all
Annual reports
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse